Format

Send to

Choose Destination
J BUON. 2019 Jan-Feb;24(1):391-396.

Ten-year experience with peritoneal mesothelioma.

Author information

1
Euromedica Kyanous Stavros, Thessaloniki, Greece.

Abstract

PURPOSE:

Peritoneal mesothelioma is a rare disease that remains confined to the peritoneal surfaces for long. Cytoreductive surgery (CRS) combined with hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is the most effective treatment and complete cytoreduction is the most significant prognostic indicator of long-term survival. This study attempted to present the results of CRS in combination with hyperthermic intraperitoneal chemotherapy in patients with peritoneal mesothelioma and identify the prognostic indicators of survival.

METHODS:

The files of patients with peritoneal mesothelioma were retrospectively reviewed. Morbidity, hospital mortality, recurrences, and the sites of recurrence were recorded. Survival and recurrence were correlated to performance status, age, extent of peritoneal dissemination, tumor grade, tumor volume, and completeness of cytoreduction.

RESULTS:

From 2005-2017, 29 patients underwent 33 cytoreductions for peritoneal mesothelioma. Hospital mortality and morbidity were 3% and 27.3% respectively. The median and 8-year survival were 66 and 62% months, respectively. The completeness of cytoreduction was the single prognostic indicator of survival, and the tumor grade the single prognostic indicator of recurrence.

CONCLUSION:

CRS combined with HIPEC is the therapeutic strategy that may provide long-term survival.

PMID:
30941996

Supplemental Content

Loading ...
Support Center